Advertisement
U.S. markets open in 9 hours 11 minutes
  • S&P Futures

    5,210.00
    -4.75 (-0.09%)
     
  • Dow Futures

    39,213.00
    -10.00 (-0.03%)
     
  • Nasdaq Futures

    18,192.75
    -38.75 (-0.21%)
     
  • Russell 2000 Futures

    2,049.80
    0.00 (0.00%)
     
  • Crude Oil

    82.52
    -0.20 (-0.24%)
     
  • Gold

    2,164.90
    +0.60 (+0.03%)
     
  • Silver

    25.33
    +0.07 (+0.28%)
     
  • EUR/USD

    1.0878
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    4.3400
    +0.0360 (+0.84%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2724
    -0.0005 (-0.04%)
     
  • USD/JPY

    149.8160
    +0.7180 (+0.48%)
     
  • Bitcoin USD

    65,550.34
    -2,127.32 (-3.14%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,701.58
    -38.82 (-0.10%)
     

Top Analyst Reports for JPMorgan, Mastercard & Qualcomm

Monday, March 16, 2020

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including JPMorgan Chase (JPM), Mastercard (MA) and Qualcomm (QCOM). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

JPMorgan’s shares have outperformed the Zacks Major Regional Banks industry over the past six months (-12.4% vs. -23.3%). The Zacks analyst believes that decent loan demand, the acquisition of InstaMed, new branch openings and focus on credit card business will continue to aid the company's financials.

The bank has surpassed the Zacks Consensus Estimate for earnings in each of the trailing four quarters. Its enhanced capital deployment plan reflects strong balance sheet position. Notably, the company has stopped its share buybacks with an aim to use the capital for lending activities amid coronavirus related slowdown.

However, the Federal Reserve's accommodative monetary policy stance is expected to hurt top-line growth in the near term. Challenges in expanding mortgage operations and the company’s significant dependence on capital markets revenues make us apprehensive and might hamper financials to some extent.

 (You can read the full research report on JPMorgan here >>>)

Shares of Mastercard have gained +17.2% over the past year against the Zacks Financial Transaction Services industry’s rise of +10.9%. The Zacks analyst believes that the company is benefiting from shifts in payments, from physical to digital.

Investment in technology has also kept the company at the forefront of the rapidly changing payments industry. Its solid capital position enables investment in business. The company has been gaining from higher switched transactions, increase in cross-border volume and gross dollar volume, and gains from acquisitions. Increase in rebates and incentives year over year was a partial dampener.

However, escalating costs might put pressure on margins. In order to gain customers and new business Mastercard has been incurring high levels of costs under rebates and incentives, which remain a concern.

(You can read the full research report on Mastercard here >>>)

Qualcomm’s shares have lost -14.2% over the past three months against the Zacks Wireless Equipment industry’s fall of -19.7%. The Zacks analyst believes that the company is poised to benefit significantly from the settlement with Apple.

Qualcomm is focused on retaining its position in the chipset market and mobile connectivity with several technological achievements and innovative product launches. It offers the flexibility and scalability needed for broad and fast 5G adoption through commercialization by OEMs. While the company expanded its leadership to the high tiers with Snapdragon 700, Snapdragon 800 solutions should continue defining the premium tier benchmarks.

However, Qualcomm is likely to face softness in demand from China with Huawei gaining prominence in the local market and OEMs managing their inventory ahead of 5G. In addition, margins have decreased sharply due to high operating expenses and R&D costs. Aggressive competition in the mobile phone chipset market is also likely to hurt profits.

(You can read the full research report on Qualcomm here >>>)

Other noteworthy reports we are featuring today include Cigna (CI), Petrobras (PBR) and Walgreens Boots Alliance (WBA).

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>

Today's Must Read

New Branches, Loans to Aid JPMorgan (JPM) Amid Zero Rates

Revenue Growth, Solid Balance Sheet Aid Mastercard (MA)

Qualcomm (QCOM) Rides on Portfolio Strength Amid Competition

Featured Reports

Express Scripts Acquisition, Revenue Growth Aid Cigna (CI)

Per the Zacks analyst, the buyout of Express Scripts has diversified Cigna's operations opening up new revenue streams; increasing membership superior products and services have led to revenue growth.

Pre-Salt Reserves Boosts Petrobras (PBR), Debt Pile Hurts

Petrobras' stakes in Brazil's attractive pre-salt oil reservoirs should boost its earnings outlook. However, the Zacks analyst is concerned over the company's huge debt load of $78.9 billion.

Retail USA Growth Aids Walgreens (WBA), LabCorp Deal a Plus

Per the Zacks analyst, efforts to improve prescription growth in Retail Pharmacy USA will aid Walgreens.

Revenues From Rides Aid Uber (UBER) Amid High Costs

The Zacks analyst is impressed by Uber's top line growth, courtesy of robust rise in revenues from rides.

U.S. Pharmaceutical Arm Aids McKesson (MCK), Competition Rife

Solid prospects in the core U.S. Pharmaceutical unit aids McKesson. The Zacks Analyst is however apprehensive about the stiff competition in the MedTech space.

Acquisitions to Support State Street (STT) Amid Low Rates

Per the Zacks analyst, business wins and strategic acquisitions over the past few years will continue to aid State Street's top line.

Higher Advertising Revenues & Affiliate Fees Aids Fox (FOXA)

Per the Zacks analyst, continued growth in advertising revenues driven by strong demand for live programming and higher affiliate fees is benefiting Fox's overall growth.

New Upgrades

Western Digital (WDC) Rides on High-Capacity HDD Adoption

Per the Zacks analyst, Western Digital is expected to gain from growing clout of higher capacity drives. Further, expansion of Ultrastar HDD family with capacities of 20 TB and 18 TB HDDs bodes well.

Cybersecurity Demand Drives NortonLifeLock's (NLOK) Growth

Per the Zacks analyst, rise in demand for cybersecurity products due to continuously increasing global hacking events is driving NortonLifeLock's top-line growth.

Acuity Brands (AYI) Rides on Product Innovation & Buyouts

Per the Zacks analysts, Acuity Brands' diversified portfolio of innovative lighting control solutions and energy-efficient luminaries, backed by acquisitions and joint ventures bode well.

New Downgrades

China Exposure and High R&D Costs to Ail General Motors (GM)

General Motors' considerable China exposure is likely to dent sales amid economic slowdown & coronavirus crisis. Further, high R&D costs might take a toll on margins, per the Zacks analyst.

High Costs & Intense Competition Hurt Dave & Buster's (PLAY)

Per the Zacks analysts, high labor costs, intense competition, and the company's limited international presence raise concerns.

American Public (APEI) Hurts From High Costs, Low Enrollment

Higher start-up costs, advertising and technology-related expenses and lower enrollment have been impacting American Public's business, per the Zacks analyst.


undefined undefined
 
Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report
 
QUALCOMM Incorporated (QCOM) : Free Stock Analysis Report
 
Petroleo Brasileiro S.A.- Petrobras (PBR) : Free Stock Analysis Report
 
Mastercard Incorporated (MA) : Free Stock Analysis Report
 
JPMorgan Chase & Co. (JPM) : Free Stock Analysis Report
 
Cigna Corporation (CI) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement